Current Report Filing (8-k)
January 20 2023 - 3:12PM
Edgar (US Regulatory)
0001867066
false
0001867066
2023-01-16
2023-01-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 16, 2023
Journey Medical Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware | |
001-41063 | |
47-1879539 |
(State or Other Jurisdiction of Incorporation) | |
(Commission File Number) | |
(IRS
Employer Identification No.) |
9237 E Via de Ventura Blvd., Suite 105
Scottsdale, AZ 85258
(Address of Principal Executive Offices)
(480) 434-6670
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act.
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act.
¨ Pre-commencement communications
pursuant to Rule 14d-2b under the Exchange Act.
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
DERM |
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On January 16, 2023, Ernest De Paolantonio, the
Chief Financial Officer of Journey Medical Corporation (the “Company”) provided notice to the Company of his resignation, effective January 27, 2023. Mr. De Paolantonio will consult with and advise the Company until March 31, 2023.
In
connection with such resignation, Joseph Benesch, age 56, the Company’s Corporate Controller, was appointed as the
Company’s interim Chief Financial Officer, effective January 27, 2023. Mr. Benesch’s compensation has not changed
as a result of this appointment. Any changes to Mr. Benesch’s compensation package, if any, will be determined by the
Company’s Board of Directors upon recommendation of its Compensation Committee.
Mr. Benesch was hired as the Company’s
Corporate Controller in November 2021. He previously served as the Principal Accounting Officer, Vice President and Corporate
Controller of Teligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate
Controller of Torrent Pharmaceuticals Ltd., a U.S. subsidiary of the Torrent Group, a multinational pharmaceutical company. Before
joining Torrent Pharmaceuticals Ltd., he held senior financial management positions from corporate controller to Vice President of
Finance at Savient Pharmaceuticals, Adare Pharmaceuticals, Inc. and Edenbridge Pharmaceuticals. He began his career in the public
accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young Global Limited, working with a diverse client base. He is
a Certified Public Accountant with an active license. Mr. Benesch is a graduate of Wilkes University where he earned a BA in
accounting.
No
family relationships exist between Mr. Benesch and any of the Company’s directors or executive officers. There are no arrangements
or understandings between Mr. Benesch and any other person pursuant to which Mr. Benesch was selected as the Company’s interim Chief
Financial Officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Benesch has a material
interest subject to disclosure under Item 404(a) of Regulation S-K.
A press release related to Mr. De Paolantonio’s departure and
Mr. Benesch’s appointment is attached as Exhibit 99.1 to this report and is incorporated by reference to this Item 5.02.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Journey Medical Corporation |
|
(Registrant) |
Date: January 20, 2023 |
|
|
By: |
/s/ Claude Maraoui |
|
|
Claude Maraoui |
|
|
Chief Executive Officer, President and Director |
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024